Acute Myeloid Leukemia Current Events

Acute Myeloid Leukemia Current Events, Acute Myeloid Leukemia News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 25 | 1000 Results
A new target in acute myeloid leukemia
Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. Dr. Daniel Tenen and colleagues from Harvard University in Boston discovered a new pathway activated by FLT3 mutation. (2012-07-16)

Identified an 'alarm clock' of a leukemia-causing oncogene
Researchers at the Bellvitge Biomedical Research Institute, led by Manel Esteller have shown that mutations in DNMT3A gene cause MEIS1 activacion, triggering leukemia. The study results are published in the journal Oncogene. (2015-10-08)

Mayo Clinic: Association between autoimmune disease and bone marrow disorders
Mayo Clinic researchers have found that azathioprine, a drug commonly used to treat autoimmune disease, may increase the risk of myeloid neoplasms. Myeloid neoplasms include a spectrum of potentially life-threatening bone marrow disorders, such as myelodysplastic syndromes and acute myeloid leukemia. The results are published in JAMA Oncology. (2017-02-02)

Noncoding RNA CCDC26 regulates KIT expression
A long noncoding RNA (lncRNA), which might give an impact on tyrosine kinase-targeted leukemia therapy, was found to be expressed in a leukemia cell line. The function of the lncRNA CCDC26 is not fully understood; however, researchers at Hiroshima University revealed the mechanisms by which CCDC26 controls the receptor tyrosine kinase KIT expression. The results provide new insights into leukemia recurrence and may help to develop new leukemia therapies. (2015-06-01)

Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors
This month in the JCI, Anthony Letai and colleagues at the Dana-Farber Cancer Institute developed an assay to determine how variability within a population of tumor cells can predict responses to chemotherapy in acute myeloid leukemia patients. (2016-09-06)

Researchers identify potential new leukemia drug target
In some cases of acute myeloid leukemia, a mutant protein is known to cause dramatic changes in gene expression. Now researchers have identified a second protein with similar function that plays an even broader role in the disease. (2015-10-22)

A code of silence in acute myeloid leukemia
In a study published in the Journal of Clinical Investigation, researchers led by Daniel Tenen at Beth Israel Deaconess Medical Center found that a transcriptional regulator known as C/EBPG was highly expressed in a subset of AML samples that had an epigenetically silenced C/EBPA gene. (2012-11-19)

Solving the mystery of NPM1 in acute myeloid leukemia
Acute myeloid leukemia (AML) cells expressing the NPM1 mutant gene are highly dependent on continued export of protein NPM1c to proliferate. This finding provides a rationale for testing nuclear export inhibitor therapeutics in NPM1-mutated AML. (2018-11-13)

For first time in 40 years, cure for acute leukemia within reach
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now. As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50 percent for lab mice with acute leukemia. (2018-08-24)

Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
Two University of Colorado Cancer Center studies show that the protein receptor Mer is overexpressed in many leukemias, and that inhibition of this Mer receptor results in the death of leukemia cells -- without affecting surrounding, healthy cells. (2013-03-11)

2-faced leukemia?
One kind of leukemia sometimes masquerades as another, according to a study published online this week in the Journal of Experimental Medicine. (2011-12-12)

Pediatric cancers: Why some forms of leukemia only affect children
Acute myeloid leukemia (AML) mainly affects children, with the prognosis often being poor despite several decades of research into more effective treatments. A new study explains why some forms of leukemia develop in very young children and identifies therapeutic targets. (2019-10-29)

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them. (2019-03-20)

Old cells, new tricks -- important clue to AML diagnosis and cure discovered
Around 22,000 people will be diagnosed this year in the US with acute myeloid leukemia (AML), the second most common type of leukemia diagnosed in adults and children. Researchers from Australia's Monash University have discovered a key reason why this disease is so difficult to treat and therefore cure. (2019-08-01)

Learning how leukemia comes to life
Acute myeloid leukemia is frequently caused by genetic alterations that affect transcription factors, such as AML1-ETO and mutations affecting genes in signal transduction pathways, such as FLT3. A JCI study reports that AML1-ETO cooperates with FLT3 to potently trigger rapid and aggressive acute leukemia in mice. This data directly support a pathogenetic model of acute leukemia, which stipulates that an activating mutation in a signal transduction pathway and a mutation in a transcription factor are required for leukemogenesis. (2005-07-14)

Closer to identifying leukemic stem cells
Researchers at the Josep Carreras Leukaemia Research Institute have developed innovative diagnostic trials to identify cells resistant to leukemia treatment. These new trials allow the identification of a subgroup of patients with an unfavorable prognosis at the time of diagnosis of acute myeloid leukemia. (2020-01-02)

Researchers harness metabolism to reverse aggressiveness in leukemia
Researchers have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of the disease. (2017-05-17)

Cancer stem cells get energy from protein, and it's proving to be their Achilles' heel
CU Cancer Center study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Clinical trial based on this observation may revolutionize care for older adults with acute myeloid leukemia. (2018-11-12)

Sequential GO and chemotherapy no benefit for older AML patients according to EORTC/GIMEMA trial
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent. (2013-10-22)

Potential seen for tailoring treatment for acute myeloid leukemia
Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia. Research on the differing drug response patterns of leukemia stem cells and blasts may show why some attempts to treat are not successful and why some patients relapse. (2018-12-07)

Unstable leukemia stem cells may predispose patients to drug resistance
The BCR-ABL gene in chronic myeloid leukemia stem cells has a tendency to quickly mutate, and this may help explain why patients are predisposed to resistance to drugs like imatinib that target that gene, according to a study in the May 2 Journal of the National Cancer Institute. (2007-05-01)

Gene's activity points to more lethal subtype of AML
A new study shows that the activity of a particular gene can identify people who have a more lethal form of acute myeloid leukemia, singling out those patients who should receive more intense therapy. The gene, called ERG (for ETS-related gene), has also been linked to chronic leukemia and to breast and prostate cancer. (2007-07-09)

CU Researchers Discover Yeast Genes Related To Human Leukemia And HIV
Two genes discovered in common baker's yeast have been found to be closely related to a family of human genes associated with a particularly severe type of leukemia and HIV-1 by a University of Colorado at Boulder research team, a surprising finding with intriguing biomedical implications. (1996-08-30)

Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells
The Institute for Research in Immunology and Cancer at the University of Montreal, in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs. (2014-03-18)

A new technique to study how myeloids become white blood cells
Researchers have created a new technique to study how myeloids, a type of blood stem cell, become the white blood cells important for immune system defense against infections and tissue damage. This approach offers new insights into the molecular mechanisms at work during myeloid differentiation, and may improve our ability to treat myeloid diseases like leukemia, the researchers report. Their findings appear in the journal Blood. (2012-10-25)

The MDS Foundation supports vidaza's recommendation for European approval
The Myelodysplastic Syndromes Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use recommending approval of vidaza for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia and acute myeloid leukemia. (2008-10-27)

Promising drug a 'new paradigm' for treating leukemia
Researchers at the University of Virginia School of Medicine have developed a compound that delays leukemia in mice and effectively kills leukemia cells in human tissue samples, raising hopes that the drug could lead to improved treatments in people. The researchers call it an exciting 'new paradigm' for treating leukemia. (2015-03-25)

AACR honors Hagop Kantarjian for outstanding clinical research
Hagop Kantarjian, M.D., chair and professor in the University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10. (2013-04-08)

Cancer research: Targeted elimination of leukemic stem cells
Cancer research in Bern has discovered a further mechanism to combat leukemia: a research team at Inselspital, Bern University Hospital and the University of Bern has succeeded in identifying an important signaling pathway for regulating leukemic stem cells. With this discovery, the researchers are expanding the arsenal of potentially highly effective drugs against leukemia. (2021-02-16)

Two-cells-in-one combo therapy could bolster leukemia treatment
A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins. (2018-10-31)

Financial relationships and prescribing practices between physicians and drug companies
In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments. (2019-02-06)

Identification of a novel tyrosine kinase inhibitor for acute myeloid leukemia
A new study in JCI Insight reports the development of a new drug that targets both resistant tumors and FLT3-independent acute myeloid leukemia. (2016-03-17)

Researchers: Myeloid malignancies underreported in US
Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001. (2012-03-28)

Baking soda treatment may help prevent leukemia relapse after stem cell transplants
Scientists have discovered that sodium bicarbonate - also known as baking soda or bicarbonate of soda - can reprogram T cells in leukemia patients to resist the immune-suppressing effects of cancer cells, which can drive leukemia relapse after stem cell transplants. (2020-10-28)

IU researchers, collaborators discover new therapeutic agents that may benefit leukemia patients
An Indiana University cancer researcher and his colleagues have discovered new therapeutic targets and drugs that may someday benefit people with certain types of leukemia or blood cancer. (2013-10-04)

Study of cancer cell metabolism yields new insights on leukemia
University of Rochester Medical Center scientists have proposed a new reason why acute myeloid leukemia, one of the most aggressive cancers, is so difficult to cure: A subset of cells that drive the disease appear to have a much slower metabolism than most other tumors cells. (2013-01-17)

Combination therapy shown as effective for higher-risk MDS/AML patients
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. (2014-12-07)

To prevent leukemia's dreaded return, go for the stem cells
Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia for good. (2012-04-05)

Many adolescent girls with leukemia are not being screened for pregnancy before beginning chemotherapy
A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (2016-10-12)

Quality-of-life issues need to be addressed for CML patients, Moffitt researchers say
Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance. The researchers say it is important to improve the patients' quality of life because most will take tyrosine kinase inhibitors for the rest of their lives. (2013-06-10)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to